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Abstract: 
The commercial calcium phosphate cement, HydroSet™, was investigated in vitro, studying 
phase formation, compressive strength and setting time, followed by an ovine in vivo study to 
measure osseointegration, bone apposition and bone-to-graft contact. The X-ray diffraction and 
31P MAS NMR results showed the initial formation of octacalcium phosphate and 
hydroxyapatite at one hour. Over seven days the octacalcium phosphate transformed to apatite, 
which was the only constituent of the cement at 28 days. This apatite phase is thought to be a 
calcium deficient apatite. In the scanning electron microscopy, histological images of twelve-
week ovine in vivo results showed a high degree of osseointegration, 92.5 %. Compressive 
strength comparisons between in vitro and in vivo measurements showed a dramatic difference 
between the in vitro measurements (highest 25.4 MPa) and in vivo (95 MPa), attributed to bone 
ingrowth into the cement in vivo. To the best of our knowledge this is the first time phase 
evolution of HydroSet™ and the properties studied in vitro complement the in vivo evaluation 
of the cement in publication. Significance of a new finding of initial formation of octacalcium 
phosphate in this cement is discussed. 
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 Introduction 
Calcium Phosphate Cements, CPCs are calcium phosphate based synthetic bone graft materials, which 
form as a result of the reactions between calcium phosphate salts1, 2. On mixing with water the salts 
react to form apatite3, the mineral phase of bone and tooth4, 5. CPCs have uses in both orthopaedics and 
dentistry where they are used as bone substitute materials to replace missing or diseased bone6. They 
are advantageous because of their injectability, which allows the surgeon to inject the setting cement 
paste into the implantation site minimally invasively7, 8. These materials are also in vivo setting which 
allows them to mould to the shape of the implantation site once implanted, which ensures complete 
void filling9, 10. Unlike CPCs, pre-set bone substitutes do not have this advantage and cannot set in vivo. 
The first commercial calcium phosphate cement was developed by Chow in 19832. In the first patent 
on calcium phosphate cements tetracalcium phosphate (TTCP) and dicalcium phosphate anhydrous 
(DCPA) (or dicalcium phosphate di-hydrous (DCPD) were used as the initial reagents. The authors 
discovered that leaving these mixtures in test tubes led to a ‘hard’ deposit after a few hours. These 
calcium phosphate salts are more soluble at neutral pH than hydroxyapatite11 and when mixed with 
water produce hydroxyapatite. As a consequence of this discovery various animal studies were 
conducted12-14 which demonstrated precipitation of nano-crystalline hydroxyapatite in these 
compositions. On implantation highly biocompatible HA was readily replaced by new bone14. This 
cement composition using TTCP and DCPA (or DCPD) was approved by the FDA in 1996 and became 
the first commercial calcium phosphate cement3. 
These cements have varied medical applications and are specifically useful in orthopaedic surgery due 
to the compositional similarity to bone. They are implanted into bone in many procedures; they are used 
in craniofacial surgery, skeletal fractures, hip replacements, vertebroplasty, kyphoplasty and in other 
corrective and restorative orthopaedic procedures15-18. 
Typical cement setting occurs via a dissolution/precipitation route1, whereby the two calcium phosphate 
salts dissolve into the aqueous solution to their constituent Ca2+ and PO43- ions. These ions then, 
precipitate to hydroxyapatite. HydroSet™ is an apatite based calcium phosphate cement consisting of 
a powder and solution, that are mixed together to initiate the setting reaction. The powder contains 
TTCP (73%) and DCPD (27%) and the solution H2O, Na2HPO4, NaH2PO4 and Polyvinylpyrrolidone 
(PVP). To the authors knowledge no previous studies have been published studying the in vitro phase 
evolution of HydroSet™. Whilst the combination TTCP and DCPD have been studied extensively 
HydroSet™ also contains polyvinylpyrrolidone in its formulation, which could potentially affect phase 
evolution. Hannink et al. studied the phase evolution in vivo and found the formation of hydroxyapatite 
within the cement; it was also found that some starting powder remained unreacted within the implant 
for up to twenty eight weeks19. 
The aim of this study was to study the in vitro and in vivo properties of the commercial calcium 
phosphate cement HydroSet™ including the structural characterisation combining the XRD and 31P 
MAS NMR. The latter allows probing the local environment of the phosphorus atoms in solids and 
delivers the detailed information regardless whether the environment is crystalline or amorphous. The 
31P MAS NMR has been shown to be specifically useful for the identification of octacalcium 
phosphate20, 21. Tseng, et al. 22 showed previously the ability of 31P MAS NMR to successfully 
differentiate between octacalcium phosphate and hydroxyapatite and even study the transition between 
the two. Another advantage of the 31P MAS NMR probe is high sensitivity that allows the detection any 
of phosphorus-containing species present in solid that are in small amounts. The in vitro aspect was to 
study phase and mechanical evolution over twenty-eight days of immersion in Tris buffer solution. 
Using an ovine femoral implant model for in vivo study we aimed to measure osseointegration, bone 
apposition and compressive strength. The ovine model was used because bone apposition rates better 
match those found in humans than the rat or rabbit model and the approximate size and weight is similar 
as to that in humans23. 
Materials & Methods 
In vitro Preparation 
HydroSet™ was mixed according to the manufacturer’s instructions to produce a paste. This cement 
paste was filled into cylindrical steel moulds with a height of 6 mm and diameter of 4 mm. The cylinders 
were ‘over–filled’ and sandwiched between two steel plates. The moulds and plates were then clamped 
together using a G clamp. The clamp was then placed into a 37C oven (Borolabs incubator, Borolabs 
Basingstoke, UK) for 120 minutes. The clamp and plates were then removed and the cements, whilst in 
the moulds were ground with silicon-carbide paper to ensure a flat surface at each end of the cylinder. 
Each cylinder was then immersed in 10 ml of Tris buffer solution, as prepared previously24, (in 15 ml 
plastic centrifuge tubes) for 1 hour, 1 day, 7 days or 28 days. Eight cement cylinders were immersed at 
each time point for each cement composition for compressive strength measurements. The samples 
were stored in a 37C oven for their respective time-points. After being stored each cylinder was 
removed and patted dry and the compressive strength measured immediately. 
Cement Property Characterisation 
Compressive Strength Measurements 
Compressive strength was measured using an Instron 5567 mechanical property testing machine 
(Instron, High Wycome, UK) using a 1kN load cell. Cylindrical specimen after their respective 
immersion periods were placed between two steel plates without drying with a 1 cm square damp filter 
paper above and below the specimen. Force was applied at a displacement rate of 1 mm/min. The test 
was stopped either automatically by the machine when fracture was detected or when it was evident by 
eye that fracture had occurred. 
Setting Time Measurement 
The setting time of each cement sample was measured using the Gilmore needle test according to the 
ISO standard ISO (9917-1:2007(E)). The HydroSet™ Cement pastes was prepared according to the 
manufacturer’s instructions, the cement paste was filled into cylindrical moulds (Height 4 mm, 
Diameter 8 mm) using a spatula. To measure the initial setting times the ‘lighter’ Gilmore needle (2.12 
mm dia. 113.4 g Wt.) was lowered onto the cement surface and left for 5 seconds, the setting time was 
taken until the needle tip no longer makes an indentation on the cement surface. To measure the final 
setting time the larger Gilmore needle (1.06 mm dia. 453.6 g Wt.) was used and again the needle was 
lowered onto the surface of the cement paste and left for 5 seconds, the final setting time was taken 
when the needle no longer makes an indentation on the cement surface. 
Cement Phase Analysis 
X-ray Powder Diffraction 
Powder XRD experiments for the cements were run on X'Pert Pro PANalytical diffractometer with 
Bragg Brentano θ/θ geometry with Cu Kα radiation operating at 45kV and 40mA. Data were collected 
from 3 to 70 2θ° in increments of 0.0334°. Beam divergence was set to ¼°. The detector used was an 
X’Celerator RTMS detector and the data collection time at each point was equivalent to 200 seconds. 
The samples were mounted on zero background silicon single crystal substrates. 
Magic Angle Spinning Nuclear Magnetic Resonance 
The 31P MAS NMR experiments were run on Bruker 600MHz spectrometer at the 242.9MHz resonance 
frequency. The powder samples were packed into 4mm rotor and spun at 11-12kHz. The measurements 
were done using 60s recycle delay and 85% H3PO4 was used to reference the chemical shift scale. 
Surgery and Test Material Administration 
All relevant licenses and Ethics approval were in place and procedures carried out in compliance with 
the UK Home Office as stated in the Animal Scientific Procedures Act (1986). Prior to surgery each 
sheep was administered the pre-med RompunTM [xylazine] and anaesthesia was induced by intravenous 
administration of ketamine and midazolam and then maintained using isoflurane and oxygen.  The 
anaesthetised animal was prepared for surgery and the medial femoral condyle was exposed by a medial 
approach.  Two holes were drilled, one in a proximal position and one in a distal position with >4mm 
between the holes.  The holes were drilled to a standard depth of 15 mm made with an 8.0 mm drill bit. 
1 mm holes were drilled either side of the defect and 1 mm tantalum beads were inserted in order to 
correctly locate the defects on retrieval using radiography.  After irrigating with sterile saline, the test 
material was pressed into place. The wound was closed and the contra-lateral medial femoral condyle 
exposed by a medial approach. In a similar manner two holes were drilled, irrigated with sterile saline, 
test materials inserted and the wound closed.  
At the time of surgery, an antibiotic injection of CeporexTM [cephalexin] was given intramuscularly at 
a dose of 5mls per animal.  Prior to recovery from anaesthesia all animals received an analgesic injection 
of VetergesicTM [2mls; 0.6mg Buprenorpine] administered as an intra-muscular injection.  CeporexTM 
injections were also given postoperatively for 3 days. VetergesicTM was administered daily on the three 
successive days post-surgery in all animals.  
Bone marking injections 
The animals received their first bone marking injection on day 63 +/- 2 (9 weeks) followed by a second 
bone marking injection 14 days later. The first bone marking injection was an intravenous 
administration of Alamycin 10 [oxytetracycline] at a dose of 15 mg/kg body weight and the other an 
intravenous administration of Calcein green at a dose of 10 mg/kg body weight.   
Terminal procedures 
The animals were sacrificed at 12 weeks post-surgery.  All animals were euthanased by an overdose of 
pentobarbital.  After sacrifice the femoral condyles including a small part of the femoral shaft were 
removed from the animal. Samples were radiographed and transverse cuts were made through each 
defect using a diamond band saw. This produced a small slab with an exposed transverse cut face of the 
implant which was surrounded by at least 5 mm of bone.  One half of each sample was used for 
mechanical testing and immersed in phosphate buffered saline.  Samples were compression tested on 
the day of sacrifice.  Specimens for histology (and following mechanical testing) were immediately 
fixed in at least 4 times the tissue volume of 10% neutral buffered formal saline. 
Laboratory phase  
Histological processing and analysis 
Each sample was dehydrated in serial dilutions of alcohol, followed by three changes in absolute alcohol 
before immersing in Chloroform to de-fat the specimens.  Specimens were returned to absolute alcohol 
before being immersed in a 50:50 solution of acrylic resin and absolute alcohol.  Samples were 
transferred to concentrated acrylic resin solution prior to being polymerized in acrylic resin.  After 
embedding, the implant and the bone were sectioned using a band saw.  Sections were taken 
longitudinally through the centre of the implant in the coronal plane.  Thin slices (100 - 60 µm) were 
then prepared using an EXAKT saw.  
Bone remodelling rates adjacent to the defect surface and within the defects were determined in these 
thin sections (100 – 60 µm) before staining. This was achieved by measuring the distance between bone 
markers under a fluorescence microscope and using our image analysis system (Figure 1). In all animals, 
bone turnover rates were calculated from regions along the length of the defect and resulted in a 
minimum of 7 regions of interest being measured per slide.   Measurements were taken using the ×5 
objective lens.  Apposition rates were calculated in µm day-1. 
 
FIGURE 1: Fluorescence microscopy of specimen 
Following fluorochrome marker measurement and analysis, thin sections were stained with Toluidine 
Blue for 15 minutes and Paragon for 10 minutes and the amount of new bone, bone-to-graft contact and 
test material present within the defect assessed using an image analysis system (Axiovision 4.5; Carl 
Zeiss, Imaging Associates Ltd, UK).   
In addition to quantifying the measurable difference between the two bone markers, image analysis was 
also used to quantify the amount of bone-cement contact. This involved capturing images along the 
entire bone-cement interface using a ×10 objective lens and a digital colour camera on the image 
analysis system. Assessments were used to evaluate the proportion of bone and soft tissue in two 
dimensions. 
Backscattered Scanning Electron Microscopy. 
Sections from each test group and at both time-points were sputter-coated and prepared for viewing 
using SEM (JEOL scanning electron microscope JEOL Welwyn Garden City, Hertfordshire, UK).  
X-ray Microtomography 
Mechanical Testing 
The compressive strength of each of the cements was tested using an indentation method in two central 
positions (at least 2 mm apart) within the cement mantle. Testing was performed on a screw driven 
Zwick Proline 500 test machine fitted with a 500 N load cell with an accuracy of 0.5 N.  Compression 
testing was performed using a custom-made jig (Figure 2). 
 
FIGURE 2: Test jig configuration for compression testing. 
The indenter was cylindrical and measured 3 mm in diameter and was positioned in the centre of the 
test specimen. Before testing could begin, the upper crosshead platen was lowered so as to just make 
contact with the specimen. In practice this was achieved by applying a preload of 2 N.  Load was applied 
axially to the specimens with a crosshead speed of 5 mm/min Specimens were loaded up to yield and 
beyond into the collapse plateau region of behaviour, as defined by Gibson25 for elastic-brittle foams. 
The compressive strength (in MPa) applied to the sample throughout the test was calculated using 
equation 1.1. 
𝐶𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑣𝑒 𝑆𝑡𝑟𝑒𝑠𝑠 =
𝐴𝑝𝑝𝑙𝑖𝑒𝑑 𝐿𝑜𝑎𝑑,𝑖𝑛 𝑁
𝜋 (𝑟𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑖𝑛𝑑𝑒𝑛𝑡𝑒𝑟,𝑖𝑛 𝑚𝑚)2
 (1.1) 
Results 
In vitro Studies 
The X-ray diffraction of the starting material in Figure 3 shows that the phases present are DCPD, 
tetracalcium phosphate and DCPA. The 31P MAS NMR of the starting material, the bottom spectrum in 
Figure 4, confirms this. At 1 hour in Tris buffer solution the XRD (Figure 5) shows the presence of 
DCPD, tetracalcium phosphate and octacalcium phosphate. The latter was identified on the X-ray 
diffraction from low intensity lines at 4.7 and 9.8 degrees two theta. The X-ray diffraction shows that 
in the 1 day, 7 day and 28 day samples two phases are present, tetracalcium phosphate and 
hydroxyapatite. The only apparent change is the relative intensities of the two phases; the tetracalcium 
phosphate decreases in relative intensity whereas the hydroxyapatite increases in its relative intensity. 
 FIGURE 3: XRD of the starting powder. 
 
FIGURE 4: 31P MAS NMR spectra for the starting powder (i) and cements matured for (ii) 1 hour, 
(iii) 1 day, (iv) 7 days and (v) 28 days of immersion in Tris buffer. The asterisks show spinning side 
bands. 
 FIGURE 5: XRD patterns of the cements matured for (i) 1 hour, (ii) 1 day, (iii) 7 days and (iv) 28 
days of immersion in Tris buffer. The open symbols are for tetracalcium phosphate; the triangles are 
for the DCPD; squares for the OCP and the diamonds for the apatite. 
The 31P MAS NMR results (Figure 4) show that at 1 hour tetracalcium phosphate is present with peaks 
at 3.8 and 5.0 ppm. There is a fairly broad shoulder at 2.8 ppm suggesting hydroxyapatite is present, as 
well as a peak at 1.4 ppm indicating a small fraction of DCPD. There are also several peaks at 3.6, 2.0 
and -0.2 ppm showing that OCP is present. The 31P MAS NMR results show tetracalcium phosphate is 
clearly still present up to 1 day of the immersion, as can be identified by the peaks at 3.8 and 4.8 ppm. 
This is true also for DCPD where a peak at 1.4 ppm is present. The peaks at -1.4 and -0.2 ppm show a 
small fraction of DCPA is still present in the cement phase from the starting materials The DCPA was 
identified only on the 31P MAS NMR and not on the X-ray diffraction by chemical shift at -1.4 and -0.2 
ppm. The 7 day 31P MAS NMR spectrum has a peak at 3.0 ppm of hydroxyapatite and two additional 
peaks at 3.7 and 4.9 ppm of tetracalcium phosphate. The 28 day sample has a main peak at 2.9 ppm 
(hydroxyapatite), a shoulder at 3.7 ppm and a very small shoulder at 4.9 ppm (tetracalcium phosphate). 
Table 1 Compressive strength of HydroSet™ immersed in Tris buffer solution at 1 hour, 1 day, 7 days 
and 28 days. 
Compressive Strength (MPa) 
1 Hour 1 Day 7 Days 28 Days 
14.2 (±1.4) 25.4 (±2.2) 13.6 (±1.8) 25.1 (±3.5) 
 
HydroSet™™ compressive strength values ranged from 13.6 to 25.4 MPa as shown in Table 1. The 
initial setting time of the HydroSet™ sample was 6 min and the final setting time was 19 min. 
 
In vivo Studies 
Bone apposition rates were measured in bone adjacent to cements in all of the thin sections prepared in 
this study. The number of measurements made per slide varied according to the distribution of the two 
markers within the bone, however, a minimal number of 7 regions of interest were measured from each 
slide. Results showed rate of bone turnover measured was 1.191 (±0.345) µm/day. Extensive % bone-
cement contact was measured in all experimental groups the mean percentage contact of 92.5 %. Results 
following mechanical tests showed that the compressive strength of samples in each of the groups was 
similar at 95 MPa (Table 2). Figures 6, 7 and 8 show photographs and electron micrographs of the 
bone/cement interface showing high levels of new bone formation on the cement surface. Figure 9 
shows an X-ray micrograph transection of the HydroSet™ within the implant site twelve weeks after 
surgery. The micrograph shows the relatively high radio-opaque HydroSet™ cement block integrated 
strongly with the trabeculae and disorganised newly formed bone surrounding the cement surface and 
adjacent trabeculae. 
Table 2 The minimum, maximum and mean compressive strength values obtained in each of the 
groups. 
Minimum (MPa) Maximum (MPa) Mean (MPa) Std. Deviation 
78.4 142.2 95.0 27.2 
 
 
 FIGURE 6: Photomicrographs of histological staining showing: Top Left) new bone formation to the 
bone-cement interface. The red arrows point to clusters of new bone formation within the older 
trabecular network. Top Right) New bone formation adjacent to the bone-HydroSet™ interface. Bottom 
Left) New bone formation within the cement. Bottom Right) New bone formation on the HydroSet™ 
surface. 
 
 
FIGURE 7:  A mosaic SEM image showing bone in contact with the cement surface around the length 
of the defect. 
Figure 7 shows a mosaic of SEM images overlaid to produce a continuous image of the cement/bone 
interface. The images show disordered bone formation surrounding both the cement and the original 
trabecular struts adjacent to the implant site. 
 
FIGURE 8: SEM micrographs showing bone in direct contact with the cement surface with 
good integration. Cracks apparent on the SEM images are artefacts and appeared during 
preparation. 
 FIGURE 9: X-ray micrograph of internal face of implanted HydroSet™ within bone. 
Discussion 
Hydroxyapatite was thought to be the only phase that forms during the setting of HydroSet™ the cement 
phase 26. However, the 31P MAS NMR and XRD results shown here revealed that the cement 
additionally forms octacalcium phosphate. Strong evidence of OCP on the 31P MAS NMR spectra is a 
peak at 3.6 ppm which would be expected if OCP was present. The other chemical shift for OCP at 3.3, 
2.0 and -0.2 ppm are partially obscured overlapping with other signals in the narrow range between -
1.4 and 5.0 ppm. The 31P MAS NMR results are in agreement with the XRD data on OCP as described 
in the previous section. 
Tseng, et al. 22 showed the transition from octacalcium phosphate to hydroxyapatite via 31P MAS NMR 
over 96 hours immersed in solution. The authors showed the initial pure octacalcium phosphate 
spectrum with resonances at 3.7, 3.3, 2.0 and -0.2 ppm and then demonstrated how the resonances at -
0.2, 2.0 and 3.7 ppm gradually decreased over six hours finally reaching relatively low intensity. 
Eventually only one resonance was remained present at around 3.0 ppm, of hydroxyapatite. The rate of 
this transition is likely to be affected by the temperature, pH and ion constituents of the immersion 
solution. It is likely that the samples containing octacalcium phosphate in our results are already in the 
process of transition into apatite since the spectra shown more closely match the five or six hour samples 
of Tseng et al, explaining the lack of relative intensity of the resonances at -0.2, 2.0 and 3.7 ppm. 
It is known that OCP often acts as a precursor to hydroxyapatite because OCP nucleates and grows 
more readily than hydroxyapatite and its formation is kinetically more favourable than that of 
hydroxyapatite under certain conditions27. Previous studies have shown this occurring in vitro27, 28 and 
there have been studies finding OCP during osteogenesis4, 29. However, it is not known from these 
results if the OCP forming is a precursor to the hydroxyapatite formation in this particular cement, or if 
it forms in addition to the hydroxyapatite. 
OCP forming calcium phosphate cements have been reported previously30 but this phase was not 
considered as a precursor species to hydroxyapatite in cements; although this may have just been due 
to difficulty in identification of the OCP phase. The main reason why no studies have previously found 
octacalcium phosphate in this setting reaction is probably because of the typically investigators study a 
reasonably narrow two theta range in copper X-ray diffraction analysis. Octacalcium phosphate and 
hydroxyapatite, due to their similar crystal structures, have similar diffraction patterns. The main 
difference is a line at 4.7 degrees two theta present in only the OCP pattern.  
The X-ray diffraction and 31P MAS NMR results show the octacalcium phosphate transforming to 
hydroxyapatite with 28 days in Tris buffer solution. Whilst the DCPD fully dissolves between 1 day 
and 7 days, the tetracalcium phosphate is still present at 28 days.  
It is believed that the reaction from OCP to hydroxyapatite can occur through crystal transition as well 
as through dissolution and reprecipitation. This crystal transition route is supported by a number of 
studies showing intercrystalline mixtures of OCP and hydroxyapatite4, 31. A crystal of partly hydrolysed 
OCP when studied on XRD gave the pattern of OCP and hydroxyapatite with the b- and c- axis collinear 
4. This suggests an intercrystalline mixture of the two crystals given the similarity in their crystal 
structure. The proposed setting reaction of HydroSet™ is listed below: 
1. 2CaHPO4.2H2O + 2Ca4(PO4)2O + H2O → Ca8(HPO4)2(PO4)4.5H2O + 2Ca2+ + 2(OH)- 
2. Ca8(HPO4)2(PO4)4.5H2O + 2Ca2+ + 2(OH)- → Ca10(PO4)6(OH)2 + 2H+ +5H2O 
 
The 31P MAS NMR was also very useful for phase identification and the detection of impurities. Whilst 
the formulation of HydroSet™ is only supposed to contain DCPD and TTCP, the NMR showed the 
presence of a small fraction of DCPA that was not detected on the X-ray diffraction. Another interesting 
result is the amount of time the tetracalcium phosphate takes to fully react to form the cement phase. 
The two starting reagents are added together in an overall calcium to phosphorus ratio of 1.67 to favour 
apatite formation26. This could be due to the relative particle sizes of the two starting reagents or lack 
of water penetrating the cement cylinder causing the dissolution of the tetracalcium phosphate and 
precipitation of the cement phase, as it has been shown particle size can have a large influence on the 
reactivity of starting components in calcium phosphate cements32. Hannink et al. showed that the TTCP 
in the cement remains until twenty six weeks after implantation in vivo19. The scanning electron 
micrographs (Figure 8) of the implant surface show residual granules within the cement block in the 
implant site, it is possible that these are remnant unreacted TTCP particles. 
Stryker, the manufacturers of HydroSet™ state that HydroSet™ has an initial setting time of 4.5 
minutes and a final setting time of 8.5 minutes 33 whereas the results using the Gilmore needle test give 
an initial setting time of 6 minutes and final setting time of 19 minutes. This difference is because the 
manufacturers use a different method to measure the initial and final setting times. This highlights that 
setting time is a difficult thing to assess and measure and especially apply this to a clinically meaningful 
context. The assessment should measure whether the material sets well enough in vivo to allow the 
clinician to easily implant it for a specific application, whilst not causing any negative effects such as 
washout or disfigurement. 
The compressive strength of the cement showed a maximum compressive strength of 25 MPa at one 
and twenty-eight days. Interestingly a decrease in compressive strength between these two points at 
seven days to 13 MPa, which correlates with and perhaps is caused by the hydrolysis of OCP to 
hydroxyapatite, identified on the phase analysis. A study performed by Clarkin et al. studied the 
mechanical properties of HydroSet™ and found compressive strengths of between 18 and 24 MPa, 
comparable to this study26. A second study performed by Van Lieshout, et al. 34 showed a similar 
compressive strength of around 11 MPa after three days of storage in water, a similar result to that found 
here. With respect to the relevance of this to clinical use these levels are approximately similar to 
vertebral bone26 and trabecular bone35.  
The in vivo results show very high rates of osseointegration for HydroSet™. The measurement of graft-
to-bone contact measured from histological images give a mean percentage contact of 92.5 %. This is 
supported in the microscopy, SEM and X-ray microtomography results. The photomicrographs of 
histological sections show the interface between the cement and original trabecula bone struts. New 
bone formation is clearly distinguishable from these images, this is especially highlighted in Figure 6 
where new bone is clearly labelled forming on both the cement surface and trabeculae present before 
surgery. Similarly the scanning electron micrographs show a strong union between the bone and cement 
surface. High osseointegration is important for stability of the bone graft within the implant site, which 
is especially important for these types of materials as they are frequently used to augment metal screws 
or augment an arthroplasty procedure. With respect to other calcium phosphate based grafting materials, 
a study by Chan et al. using the same animal model showed bone-to-graft contact of <50% for a 
hydroxyapatite based granular bone substitute implanted for a similar period36. 
A study performed by Hannink et al. implanted HydroSet™ into the distal femur of rabbits19. The 
authors measured percentage bone contact between the cement and new bone at six, twenty six and fifty 
two weeks of implantation. Percentage contact was approximately 80-85% bone-to-graft contact, for 
all time points measured. The authors also compared Norian SRS and BoneSource in the same study 
and found similar levels of bone contact for these too. These levels are similar to what was measured 
here and therefore suggest high levels of osseointegration are associated with calcium phosphate 
cements. It should be noted that all of the cements studied consist of mixtures of TTCP and DCPD19. A 
study by Flautre et al.37 implanted four compositions of injectable calcium phosphate cement in an distal 
femur ovine animal model. The authors compared a Brushite forming calcium phosphate cement 
(BCPC), an empty site and defects filled with autologous bone. Although the authors did not directly 
measure bone-to-graft contact, the microradiographs presented in the paper showed very limited 
osseointegration in the implant site. The authors found bone apposition rates of 1.5 µm day-1 for the 
BCPC, 1.2 µm day-1 for the empty site and 1.1 µm day-1 for the autograft at 24 weeks. The ovine model 
is believed to accurately represent bone apposition rates compared to that in humans23. The bone 
apposition rate, in the results presented here, was measured as 1.191 (± 0.345) µm day-1, with respect 
to other bone substitutes this value is comparable to other injectable calcium phosphate cements 
implanted within sheep.  
The considerably higher in vivo compressive strength compared to that measured in vitro was 
surprising. The highest in vitro compressive strength measurement was 25 MPa whereas in vivo at 
twelve weeks this value was 94 MPa. The cause of this increase is likely due to the ingrowth of bone 
(shown on the histology) into the cement pores that would have been ‘unfilled’ in vitro. This explanation 
is supported by the results of Van Lieshout, et al. 34 who showed that porosity and compressive strength 
are negatively correlated. This result also raises questions with respect to the in vitro measurements of 
bone cements and their validity. Calcium phosphate cements are sometimes dismissed for certain 
applications due to their relatively low, in vitro, mechanical properties in favour of stronger acrylic or 
ionomer bone cements. These results suggest that in vivo these cements are actually much stronger, due 
to their ability to osseointegrate, than previously thought. 
One of the most significant aspects of this paper is the discovery of the formation of octacalcium 
phosphate. The HydroSet™ starting reagents are identical to those originally formulated in CPCs (and 
is commonly used in commercial examples) it is likely that many other CPC formulations also form 
OCP but it has not been previously identified. Octacalcium phosphate has been shown to enhance bone 
formation in vivo 38, 39, have a positive impact on cell proliferation40, and resorbs more readily than 
hydroxyapatite41. 
Conclusions 
The paper presented phase evolution, properties and in vivo study of the HydroSet™ cement. In addition 
to apatite phase known to form as a result of the setting, the phase of the OCP was also found at early 
stage in the cement. This implies that a number of other cements including commercially available that 
use similar starting calcium phosphates form OCP during the setting. In HydroSet™ in vitro results 
showed an initial setting time of 6 minutes, a final setting time of 19 minutes and maximum compressive 
strength of 25MPa. In vivo results showed bone apposition rates of 1.191 (± 0.345) µm day-1, bone-to-
graft contact of 92.5 % and an in vivo compressive strength of 95 MPa. Comparisons on the in vitro and 
in vivo showed that HydroSet™ is considerably stronger in vivo compared to in vitro, the cause of this 
attributed to bone formation within the cement pores and a high degree of osseointegration. 
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